News and Announcements
CannPal to present at the 2019 Asian Hemp Investment Summit
- Published June 26, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CannPal is presenting at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019
- Managing Director, Layton Mills, will be presenting on the Company’s progress and the opportunity for cannabinoids in the animal health market in Asia
- Mr Mills’s presentation is attached to this release.
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to attach a presentation that will be delivered by CannPal Managing Director, Mr Layton Mills, at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019.
The purpose of the summit is to bring together cannabis industry leaders from all over the world, including expert groups on cannabis legislation in various countries, investment groups, and medical scientific research experts, to support the development of the Asian cannabis industry.
The forum is being co-hosted by the CBDG-Cannabis Industrial Fund alongside Arcview Group. The Arcview Investor Network includes more than 600 accredited investors who have put more than US$190 million behind 175 companies since inception.
About CannPal Animal Therapeutics
CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovate therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
